Search results for CD16 Antibody

Anti-CD16 antibody [EPR16784] - C-terminal, Abcam, AB198507

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

PE Anti-CD16 antibody [EPR22409-124], Abcam, AB270141

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Anti-Human CD16 Antibody (3G8) (HY386107), abinScience, HY386107

HRP Anti-CD16 antibody [SP189] (C-terminal), Abcam, AB306216

This conjugated primary antibody is "made to order" and it is released using a quantitative quality control method that ensures binding affinity and labelling efficiency of the conjugate. Via leveraging the power of the Lightning-Link ® conjugation technology , Abcam will deliver highly consistent recombinant conjugates in <2 weeks, giving you access to an ever growing portfolio of antibody-label combinations. For suitable applications and species reactivity, please refer to the unconjugated version of this clone. How are conjugated primary antibodies validated? This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling. For suitable applications and species reactivity, please refer to the unconjugated version of this clone. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

PE/Cy7® Anti-CD16 antibody [3G8], Abcam, AB234209

This product or portions thereof is manufactured under license from Carnegie Mellon University under U.S. Patent Number 5, 268, 486 and related patents. Cy® and CyDye® are trademarks of Cytiva.

PerCP/Cy5.5® Anti-CD16 antibody [3G8], Abcam, AB157322

Purified antibody is conjugated with tandem dye PerCP/Cy5.5 ® under optimum conditions. The conjugate is purified by size-exclusion chromatography and adjusted for direct use. No reconstitution is necessary.

violetFluor™ 450 Anti-CD16 antibody [3G8], Abcam, AB272250

APC Anti-CD16 antibody [SP189] (C-terminal), Abcam, AB306215

This conjugated primary antibody is "made to order" and it is released using a quantitative quality control method that ensures binding affinity and labelling efficiency of the conjugate. Via leveraging the power of the Lightning-Link ® conjugation technology , Abcam will deliver highly consistent recombinant conjugates in <2 weeks, giving you access to an ever growing portfolio of antibody-label combinations. For suitable applications and species reactivity, please refer to the unconjugated version of this clone. How are conjugated primary antibodies validated? This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling. For suitable applications and species reactivity, please refer to the unconjugated version of this clone. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

APC/Cy7® Anti-CD16 antibody [3G8], Abcam, AB197141

Anti-CD16 antibody [015] - BSA and Azide free, Abcam, AB276040